Tags

Type your tag names separated by a space and hit enter

Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial.
Trials 2015; 16:521T

Abstract

BACKGROUND

A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control.

METHODS

In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student's t-test and paired t-test.

RESULTS

After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (-19.4 ± 5.62 mg/dL) and 60 minutes (-15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (-27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose.

CONCLUSIONS

Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus.

TRIAL REGISTRATION

ClinicalTrials.gov NCT02285231 . Registered 11 May 2014.

Authors+Show Affiliations

Department of Food and Nutrition, National Research Laboratory for Clinical Nutrigenetics/Nutrigenomics, Yonsei University, Seoul, 120-749, Republic of Korea. hyukhg@daum.net.R&D Center, CHA BioMed and Department of Applied Science, CHA University, Gyeonggi-do, 463-836, Republic of Korea. jhyun4615@naver.com.Department of Food and Nutrition, National Research Laboratory for Clinical Nutrigenetics/Nutrigenomics, Yonsei University, Seoul, 120-749, Republic of Korea. hyun4615@hanmail.net. Research Institute of Science for Aging, Yonsei University, Seoul, 120-749, Republic of Korea. hyun4615@hanmail.net.R&D Center, CHA BioMed and Department of Applied Science, CHA University, Gyeonggi-do, 463-836, Republic of Korea. lkh1@chamc.co.kr.Department of Food and Nutrition, Hannam University, Daejeon, 305-811, Republic of Korea. youngk@hnu.kr.R&D Center, CHA BioMed and Department of Applied Science, CHA University, Gyeonggi-do, 463-836, Republic of Korea. hoe@cha.ac.kr.Department of Food and Nutrition, National Research Laboratory for Clinical Nutrigenetics/Nutrigenomics, Yonsei University, Seoul, 120-749, Republic of Korea. jhleeb@yonsei.ac.kr. Research Institute of Science for Aging, Yonsei University, Seoul, 120-749, Republic of Korea. jhleeb@yonsei.ac.kr.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26578409

Citation

Park, Su Eun, et al. "Antihyperglycemic Effect of Short-term Arginyl-fructose Supplementation in Subjects With Prediabetes and Newly Diagnosed Type 2 Diabetes: Randomized, Double-blinded, Placebo-controlled Trial." Trials, vol. 16, 2015, p. 521.
Park SE, Kim OH, Kwak JH, et al. Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial. Trials. 2015;16:521.
Park, S. E., Kim, O. H., Kwak, J. H., Lee, K. H., Kwon, Y. I., Chung, K. H., & Lee, J. H. (2015). Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial. Trials, 16, p. 521. doi:10.1186/s13063-015-1036-z.
Park SE, et al. Antihyperglycemic Effect of Short-term Arginyl-fructose Supplementation in Subjects With Prediabetes and Newly Diagnosed Type 2 Diabetes: Randomized, Double-blinded, Placebo-controlled Trial. Trials. 2015 Nov 14;16:521. PubMed PMID: 26578409.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial. AU - Park,Su Eun, AU - Kim,Ok-Hwan, AU - Kwak,Jung Hyun, AU - Lee,Kwang-Hyoung, AU - Kwon,Young-In, AU - Chung,Kwang Hoe, AU - Lee,Jong Ho, Y1 - 2015/11/14/ PY - 2015/02/09/received PY - 2015/10/27/accepted PY - 2015/11/19/entrez PY - 2015/11/19/pubmed PY - 2016/7/28/medline SP - 521 EP - 521 JF - Trials JO - Trials VL - 16 N2 - BACKGROUND: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. METHODS: In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student's t-test and paired t-test. RESULTS: After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (-19.4 ± 5.62 mg/dL) and 60 minutes (-15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (-27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose. CONCLUSIONS: Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus. TRIAL REGISTRATION: ClinicalTrials.gov NCT02285231 . Registered 11 May 2014. SN - 1745-6215 UR - https://www.unboundmedicine.com/medline/citation/26578409/Antihyperglycemic_effect_of_short_term_arginyl_fructose_supplementation_in_subjects_with_prediabetes_and_newly_diagnosed_type_2_diabetes:_randomized_double_blinded_placebo_controlled_trial_ L2 - https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1036-z DB - PRIME DP - Unbound Medicine ER -